Cambridge Cog Regulatory News (COG)

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

New client signs with Cognition Kit software

The digital neuroscience company Cambridge Cognition Holdings plc, (AIM: COG, 'the Company'), which develops and markets digital solutions to assess brain health, has announced a new $0.5m contract with a major pharmaceutical company for the use of its Cognition Kit™ digital health software in a clinical trial.

Cognition Kit measures cognitive health on mobile and wearable devices, enabling researchers to gather data in everyday life and clinicians to make more insightful treatment decisions for their patients.

This clinical trial will monitor patients diagnosed with a neurological condition for 12 months. During this time, participants will use a Cognition Kit smartphone app to test their brain health remotely and frequently, providing the sponsor with rich real-world data outside of clinical sites in a more holistic, cost-effective and patient-centric fashion.

The new contract follows the Company's successful collaborations with existing Cognition Kit partners and further negotiations with other major pharmaceutical companies are at an advanced stage.

Dr Steven Powell, Chief Executive Officer, at Cambridge Cognition said: "The pharmaceutical industry is increasingly looking to develop novel biomarkers and use digital phenotyping techniques to improve their data intelligence and market access. Having successfully demonstrated the effectiveness of Cognition Kit technology through our ongoing partnership with Takeda, we are delighted to be signing additional clients with whom we expect to establish long-lasting commercial partnerships."

Enquiries

About Cognition Kit Limited

Cognition Kit is a joint venture between Cambridge Cognition and Ctrl Group formed to develop scientifically valid digital health apps on mobile and wearable devices. Cognition Kit software takes research out of the lab and into everyday life, enabling doctors, scientists and the public to better understand and manage brain health.

For further information visit www.cognitionkit.com 

About Cambridge Cognition Holdings PLC

Cambridge Cognition is a digital neuroscience company developing software products to better understand, detect and treat brain health conditions. The company's cognitive technologies are used to accelerate the research and development of new treatments, enhance understanding of the brain and accurately assess cognitive health in patients worldwide.

For further information visit www.cambridgecognition.com